Zoci Hits 40% Confirmed Response Rate in Hard-to-Treat Neuroendocrine Carcinomas
ZLAB sits 45% above its 52-week low of $15.96.
Summary
Zai Lab's DLL3 ADC zoci posted a 40.0% confirmed objective response rate (24/60) and 55.0% disease control rate in previously treated extrapulmonary neuroendocrine carcinomas, with responses across GEP-NEC (35.9%) and other epNEC subtypes (47.6%). Median duration of response was 5.6 months, and safety looked clean: 12.8% Grade ≥3 treatment-related adverse events across 133 patients, no Grade ≥3 ILD, and a 0.8% treatment-related discontinuation rate. The company has finished enrolling the Phase 2 second-line expansion and, with FDA feedback, is pursuing accelerated approval on that single-arm study, with topline data expected in 2027; a global Phase 3 first-line maintenance trial is planned to start next year. This is the key pipeline asset management has flagged as Zai Lab's first potential global oncology launch, so the data carry weight beyond the current revenue base — Q3 product revenue fell 7% and the company just raised $250M at $22.04 per ADS. Full presentation is tomorrow at NANETS in Las Vegas.
At the time of this announcement, ZLAB was trading at $23.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $15.96 to $27.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.